15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Causes of death in men with localized prostate cancer: a nationwide, population‐based study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To detail the distribution of causes of death from localized prostate cancer ( PCa).

          Patients and Methods

          The database PCBase Sweden links the Swedish National Prostate Cancer Register with other nationwide population‐based healthcare registers. We selected all 57 187 men diagnosed with localized PCa between 1997 and 2009 and their 114 374 PCa‐free control subjects, matched according to age and county of residence. Mortality was calculated using competing risk regression analyses, taking into account PCa risk category, age and Charlson comorbidity index ( CCI).

          Results

          In men with low‐risk PCa, all‐cause mortality was lower compared with that in corresponding PCa‐free men: 10‐year all‐cause mortality was 18% for men diagnosed at age 70 years, with a CCI score of 0, and 21% among corresponding control subjects. Of these cases, 31% died from cardiovascular disease ( CVD) compared with 37% of the corresponding control subjects. For men with low‐risk PCa, 10‐year PCa‐mortality was 0.4, 1 and 3% when diagnosed at age 50, 60 and 70 years, respectively. PCa was the third most common cause of death (18%), after CVD (31%) and other cancers (30%). By contrast, PCa was the most common cause of death in men with intermediate‐ and high‐risk localized PCa.

          Conclusions

          Men with low‐risk PCa had lower all‐cause mortality than PCa‐free men because of lower CVD mortality, driven by early detection selection; however, for men with intermediate‐ or high‐risk disease, the rate of PCa death was substantial, irrespective of CCI score, and this was even more pronounced for those diagnosed at age 50 or 60 years.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: found
          • Article: not found

          Outcomes of localized prostate cancer following conservative management.

          Most newly diagnosed prostate cancers are clinically localized, and major treatment options include surgery, radiation, or conservative management. Although conservative management can be a reasonable choice, there is little contemporary prostate-specific antigen (PSA)-era data on outcomes with this approach. To evaluate the outcomes of clinically localized prostate cancer managed without initial attempted curative therapy in the PSA era. A population-based cohort study of men aged 65 years or older when they were diagnosed (1992-2002) with stage T1 or T2 prostate cancer and whose cases were managed without surgery or radiation for 6 months after diagnosis. Living in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program, the men were followed up for a median of 8.3 years (through December 31, 2007). Competing risk analyses were performed to assess outcomes. Ten-year overall survival, cancer-specific survival, and major cancer related interventions. Among men who were a median age of 78 years at cancer diagnosis, 10-year prostate cancer-specific mortality was 8.3% (95% confidence interval [CI], 4.2%-12.8%) for men with well-differentiated tumors; 9.1% (95% CI, 8.3%-10.1%) for those with moderately differentiated tumors, and 25.6% (95% CI, 23.7%-28.3%) for those with poorly differentiated tumors. The corresponding 10-year risks of dying of competing causes were 59.8% (95% CI, 53.2%-67.8%), 57.2% (95% CI, 52.6%-63.9%), and 56.5% (95% CI, 53.6%-58.8%), respectively. Ten-year disease-specific mortality for men aged 66 to 74 years diagnosed with moderately differentiated disease was 60% to 74% lower than earlier studies: 6% (95% CI, 4%-8%) in the contemporary PSA era (1992-2002) compared with results of previous studies (15%-23%) in earlier eras (1949-1992). Improved survival was also observed in poorly differentiated disease. The use of chemotherapy (1.6%) or major interventions for spinal cord compression (0.9%) was uncommon. Results following conservative management of clinically localized prostate cancer diagnosed from 1992 through 2002 are better than outcomes among patients diagnosed in the 1970s and 1980s. This may be due, in part, to additional lead time, overdiagnosis related to PSA testing, grade migration, or advances in medical care.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

            Limited data exist on long-term outcomes among men with prostate cancer (PCa) from population-based cohorts incorporating information on clinical risk category. To assess 15-yr mortality for men with PCa treated with noncurative intent according to clinical stage, Gleason score (GS), serum levels of prostate specific antigen (PSA), comorbidity, and age. Register-based cohort study of 76 437 cases in the National Prostate Cancer Register (NPCR) of Sweden diagnosed from 1991 through 2009 and treated with noncurative intent. Each case was placed in one of five risk categories: (1) low risk: T1-T2 tumor, PSA level <10 ng/ml, and GS ≤6; (2) intermediate risk: T1-T2 tumor and PSA level 10-<20 ng/ml or GS 7; (3) high risk: T3 tumor or PSA level 20-<50 ng/ml or GS ≥8; (4) regional metastases: N1 or T4 tumor or PSA level 50-100 ng/ml; and (5) distant metastases: M1 tumor or PSA ≥100 ng/ml. Ten- and 15-yr cumulative risk of death after diagnosis from PCa, cardiovascular disease, and other causes. Among men with a Charlson Comorbidity Index (CCI) score of 0, no differences were found in observed versus expected all-cause mortality in the low-risk group. Observed mortality was only slightly greater in the intermediate-risk group, but men with high-risk localized PCa or more advanced disease had substantially higher mortality than expected. CCI was strongly associated with cumulative 10-yr mortality from causes other than PCa, especially for men <65 yr. Limitations include potential misclassification in risk category due to GS assignment. PCa mortality rates vary 10-fold according to risk category. The risk of death from causes other than PCa is most strongly related to comorbidity status in younger men. Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer.

              Although demographic, clinicopathologic, and socioeconomic differences may affect treatment and outcomes of prostate cancer, the effect of mental health disorders remains unclear. We assessed the effect of previously diagnosed depression on outcomes of men with newly diagnosed prostate cancer.
                Bookmark

                Author and article information

                Journal
                BJU Int
                BJU Int
                10.1111/(ISSN)1464-410X
                BJU
                Bju International
                John Wiley and Sons Inc. (Hoboken )
                1464-4096
                1464-410X
                15 May 2015
                March 2016
                : 117
                : 3 ( doiID: 10.1111/bju.2016.117.issue-3 )
                : 507-514
                Affiliations
                [ 1 ] Division of Cancer Studies Cancer Epidemiology Group School of MedicineKing's College London LondonUK
                [ 2 ] Regional Cancer CentreUppsala Örebro UppsalaSweden
                [ 3 ] CLINTEC DepartmentKarolinska Institutet StockholmSweden
                [ 4 ] Clinical Epidemiology Unit Department of Medicine (Solna)Karolinska Institute StockholmSweden
                [ 5 ] Department of Surgical SciencesUppsala University UppsalaSweden
                [ 6 ] Department of Surgical and Perioperative Sciences, Urology and AndrologyUmeå University UmeåSweden
                Author notes
                [*] [* ] Correspondence: Mieke Van Hemelrijck, Division of Cancer Studies, Cancer Epidemiology Group, Research Oncology, School of Medicine, King's College London, 3rd Floor, Bermondsey Wing, Guy's Hospital, London SE1 9RT, UK.

                e‐mail: mieke.vanhemelrijck@ 123456kcl.ac.uk

                Article
                BJU13059
                10.1111/bju.13059
                4832314
                25604807
                9d968fd4-733f-48d9-9ec1-dabe5c07617f
                © 2015 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Pages: 8
                Funding
                Funded by: Swedish Research Council
                Award ID: 825‐2008‐5910
                Funded by: Stockholm Cancer Society
                Funded by: Cancer Research UK
                Funded by: Swedish Council for Working Life and Social Research
                Funded by: Västerbotten County Council
                Categories
                Translational Science
                Translational Science
                Custom metadata
                2.0
                bju13059
                March 2016
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.1 mode:remove_FC converted:23.06.2016

                Urology
                comorbidities,prostate cancer death,curative treatment,localized disease
                Urology
                comorbidities, prostate cancer death, curative treatment, localized disease

                Comments

                Comment on this article